Do analysts recommend UNCY or VIRI?

Unicycive Therapeutics presently has a consensus target price of $18.25, suggesting a potential upside of 389.28%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Unicycive Therapeutics is more favorable than Virios Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Unicycive Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is UNCY or VIRI more profitable?

Unicycive Therapeutics' return on equity of -91.50% beat Virios Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Unicycive Therapeutics N/A -91.50% -61.47% Virios Therapeutics N/A -130.33% -115.00%

Do analysts prefer VIRI or AARD?

Aardvark Therapeutics has a consensus target price of $13.13, indicating a potential upside of 224.88%. Given Aardvark Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aardvark Therapeutics is more favorable than Virios Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aardvark Therapeutics 2 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.36

Which has stronger valuation and earnings, VIRI or AARD?

Virios Therapeutics is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virios Therapeutics N/A N/A -$5.30M -$0.27 N/A Aardvark Therapeutics N/A N/A -$57.59M -$3.21 N/A

Is VIRI or AARD more profitable?

Aardvark Therapeutics' return on equity of -71.54% beat Virios Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Virios Therapeutics N/A -130.33% -115.00% Aardvark Therapeutics N/A -71.54% -64.94%

Do analysts rate LENZ or VIRI?

LENZ Therapeutics presently has a consensus target price of $28.80, indicating a potential upside of 747.06%. Given LENZ Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe LENZ Therapeutics is more favorable than Virios Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LENZ Therapeutics 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50 Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer IMUX or VIRI?

Immunic currently has a consensus target price of $35.43, indicating a potential upside of 414.20%. Given Immunic's stronger consensus rating and higher probable upside, equities analysts plainly believe Immunic is more favorable than Virios Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunic 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.00 Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, IMUX or VIRI?

Virios Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunic N/A N/A -$97.17M -$4.38 N/A Virios Therapeutics N/A N/A -$5.30M -$0.27 N/A

Is IMUX or VIRI more profitable?

Virios Therapeutics' return on equity of -130.33% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Immunic N/A -157.89% -107.88% Virios Therapeutics N/A -130.33% -115.00%

Do analysts prefer VIRI or VANI?

Vivani Medical has a consensus price target of $3.75, suggesting a potential upside of 217.80%. Given Vivani Medical's stronger consensus rating and higher possible upside, analysts plainly believe Vivani Medical is more favorable than Virios Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Vivani Medical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has higher valuation and earnings, VIRI or VANI?

Virios Therapeutics is trading at a lower price-to-earnings ratio than Vivani Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virios Therapeutics N/A N/A -$5.30M -$0.27 N/A Vivani Medical N/A N/A -$26.61M -$0.35 N/A

Is VIRI or VANI more profitable?

Virios Therapeutics' return on equity of -130.33% beat Vivani Medical's return on equity. Company Net Margins Return on Equity Return on Assets Virios Therapeutics N/A -130.33% -115.00% Vivani Medical N/A -191.05% -70.91%

Virios Therapeutics (VIRI) Competitors

$1.30 -0.07 (-5.11%)

As of 10/13/2026

Compare

VIRI vs. UNCY, AARD, LENZ, IMUX, and VANI

Should you buy Virios Therapeutics stock or one of its competitors? Virios Therapeutics's main competitors and comparable companies include Unicycive Therapeutics (UNCY), Aardvark Therapeutics (AARD), LENZ Therapeutics (LENZ), Immunic (IMUX), and Vivani Medical (VANI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Virios Therapeutics compare to Unicycive Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

In the previous week, Unicycive Therapeutics had 11 more articles in the media than Virios Therapeutics. MarketBeat recorded 11 mentions for Unicycive Therapeutics and 0 mentions for Virios Therapeutics. Unicycive Therapeutics' average media sentiment score of 0.06 beat Virios Therapeutics' score of 0.00 indicating that Unicycive Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Unicycive Therapeutics	Neutral
Virios Therapeutics	Neutral

Unicycive Therapeutics has a beta of 1.83, suggesting that its share price is 83% more volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market.

Unicycive Therapeutics' return on equity of -91.50% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-91.50%	-61.47%
Virios Therapeutics	N/A	-130.33%	-115.00%

40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are held by institutional investors. 6.0% of Unicycive Therapeutics shares are held by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Unicycive Therapeutics presently has a consensus target price of $18.25, suggesting a potential upside of 389.28%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Unicycive Therapeutics is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Virios Therapeutics has lower revenue, but higher earnings than Unicycive Therapeutics. Virios Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	152.77	-$26.56M	-$1.75	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

Summary

Unicycive Therapeutics beats Virios Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Virios Therapeutics compare to Aardvark Therapeutics?

Virios Therapeutics (NASDAQ:VIRI) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

In the previous week, Aardvark Therapeutics had 26 more articles in the media than Virios Therapeutics. MarketBeat recorded 26 mentions for Aardvark Therapeutics and 0 mentions for Virios Therapeutics. Aardvark Therapeutics' average media sentiment score of 0.14 beat Virios Therapeutics' score of 0.00 indicating that Aardvark Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Virios Therapeutics	Neutral
Aardvark Therapeutics	Neutral

Aardvark Therapeutics' return on equity of -71.54% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virios Therapeutics	N/A	-130.33%	-115.00%
Aardvark Therapeutics	N/A	-71.54%	-64.94%

Aardvark Therapeutics has a consensus target price of $13.13, indicating a potential upside of 224.88%. Given Aardvark Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aardvark Therapeutics is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.36

Virios Therapeutics is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

9.1% of Virios Therapeutics shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by insiders. Comparatively, 17.8% of Aardvark Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Virios Therapeutics has a beta of 1.58, indicating that its share price is 58% more volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 3.8, indicating that its share price is 280% more volatile than the broader market.

Summary

Aardvark Therapeutics beats Virios Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Virios Therapeutics compare to LENZ Therapeutics?

LENZ Therapeutics (NASDAQ:LENZ) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

LENZ Therapeutics has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market.

In the previous week, LENZ Therapeutics had 2 more articles in the media than Virios Therapeutics. MarketBeat recorded 2 mentions for LENZ Therapeutics and 0 mentions for Virios Therapeutics. LENZ Therapeutics' average media sentiment score of 0.95 beat Virios Therapeutics' score of 0.00 indicating that LENZ Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
LENZ Therapeutics	Positive
Virios Therapeutics	Neutral

LENZ Therapeutics presently has a consensus target price of $28.80, indicating a potential upside of 747.06%. Given LENZ Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe LENZ Therapeutics is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 8.3% of LENZ Therapeutics shares are owned by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Virios Therapeutics has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -586.74%. LENZ Therapeutics' return on equity of -53.39% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	-586.74%	-53.39%	-49.14%
Virios Therapeutics	N/A	-130.33%	-115.00%

Virios Therapeutics has lower revenue, but higher earnings than LENZ Therapeutics. Virios Therapeutics is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$19.09M	5.60	-$82.13M	-$4.09	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

Summary

LENZ Therapeutics beats Virios Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Virios Therapeutics compare to Immunic?

Immunic (NASDAQ:IMUX) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

Virios Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$4.38	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

In the previous week, Immunic had 8 more articles in the media than Virios Therapeutics. MarketBeat recorded 8 mentions for Immunic and 0 mentions for Virios Therapeutics. Immunic's average media sentiment score of 0.41 beat Virios Therapeutics' score of 0.00 indicating that Immunic is being referred to more favorably in the media.

Company	Overall Sentiment
Immunic	Neutral
Virios Therapeutics	Neutral

51.8% of Immunic shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 5.5% of Immunic shares are owned by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Immunic has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market.

Virios Therapeutics' return on equity of -130.33% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-157.89%	-107.88%
Virios Therapeutics	N/A	-130.33%	-115.00%

Immunic currently has a consensus target price of $35.43, indicating a potential upside of 414.20%. Given Immunic's stronger consensus rating and higher probable upside, equities analysts plainly believe Immunic is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Immunic beats Virios Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Virios Therapeutics compare to Vivani Medical?

Virios Therapeutics (NASDAQ:VIRI) and Vivani Medical (NASDAQ:VANI) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

Vivani Medical has a consensus price target of $3.75, suggesting a potential upside of 217.80%. Given Vivani Medical's stronger consensus rating and higher possible upside, analysts plainly believe Vivani Medical is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Vivani Medical had 2 more articles in the media than Virios Therapeutics. MarketBeat recorded 2 mentions for Vivani Medical and 0 mentions for Virios Therapeutics. Vivani Medical's average media sentiment score of 1.25 beat Virios Therapeutics' score of 0.00 indicating that Vivani Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Virios Therapeutics	Neutral
Vivani Medical	Positive

Virios Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market. Comparatively, Vivani Medical has a beta of 2.35, suggesting that its stock price is 135% more volatile than the broader market.

9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 6.8% of Vivani Medical shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by company insiders. Comparatively, 53.3% of Vivani Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Virios Therapeutics' return on equity of -130.33% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virios Therapeutics	N/A	-130.33%	-115.00%
Vivani Medical	N/A	-191.05%	-70.91%

Virios Therapeutics is trading at a lower price-to-earnings ratio than Vivani Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A
Vivani Medical	N/A	N/A	-$26.61M	-$0.35	N/A

Summary

Vivani Medical beats Virios Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Virios Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VIRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VIRI vs. The Competition

Export

Metric	Virios Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$25.04M	$12.40B	$7.29B	$12.91B
Dividend Yield	N/A	2.63%	2.51%	22.89%
P/E Ratio	-4.81	807.80	275.68	25.25
Price / Sales	N/A	748.52	562.78	78.51
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	6.50	9.19	10.54	5.92
Net Income	-$5.30M	$2.84B	$3.50B	$381.16M
7 Day Performance	-14.47%	-4.30%	-4.13%	-4.32%
1 Month Performance	-32.99%	-8.36%	-8.51%	-7.19%
1 Year Performance	-78.96%	-6.14%	2.12%	-4.99%

Virios Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VIRI Virios Therapeutics	N/A	$1.30 -5.1%	N/A	-74.5%	$25.04M	N/A	N/A	5	News Coverage
UNCY Unicycive Therapeutics	2.7205 of 5 stars	$4.23 +1.0%	$18.25 +331.4%	-16.9%	$116.71M	N/A	N/A	22	Trending News
AARD Aardvark Therapeutics	3.1895 of 5 stars	$5.04 -3.4%	$13.13 +160.4%	-72.4%	$114.24M	N/A	N/A	28	Analyst Forecast High Trading Volume
LENZ LENZ Therapeutics	2.8524 of 5 stars	$3.79 +5.6%	$28.80 +659.9%	-91.2%	$112.80M	$21.48M	N/A	152	Positive News
IMUX Immunic	2.6315 of 5 stars	$7.82 -3.1%	$35.43 +353.1%	-23.0%	$110.11M	N/A	N/A	95

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VIRI) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Virios Therapeutics (VIRI) Competitors

VIRI vs. UNCY, AARD, LENZ, IMUX, and VANI

How does Virios Therapeutics compare to Unicycive Therapeutics?

Summary

How does Virios Therapeutics compare to Aardvark Therapeutics?

Summary

How does Virios Therapeutics compare to LENZ Therapeutics?

Summary

How does Virios Therapeutics compare to Immunic?

Summary

How does Virios Therapeutics compare to Vivani Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIRI vs. The Competition

Virios Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Virios Therapeutics (VIRI) Competitors

VIRI vs. UNCY, AARD, LENZ, IMUX, and VANI

How does Virios Therapeutics compare to Unicycive Therapeutics?

Does the media prefer UNCY or VIRI?

Which has more risk & volatility, UNCY or VIRI?

Is UNCY or VIRI more profitable?

Do insiders and institutionals hold more shares of UNCY or VIRI?

Do analysts recommend UNCY or VIRI?

Which has stronger earnings and valuation, UNCY or VIRI?

Summary

How does Virios Therapeutics compare to Aardvark Therapeutics?

Does the media refer more to VIRI or AARD?

Is VIRI or AARD more profitable?

Do analysts prefer VIRI or AARD?

Which has stronger valuation and earnings, VIRI or AARD?

Do insiders and institutionals have more ownership in VIRI or AARD?

Which has more volatility and risk, VIRI or AARD?

Summary

How does Virios Therapeutics compare to LENZ Therapeutics?

Which has more volatility and risk, LENZ or VIRI?

Does the media prefer LENZ or VIRI?

Do analysts rate LENZ or VIRI?

Do insiders & institutionals believe in LENZ or VIRI?

Is LENZ or VIRI more profitable?

Which has preferable valuation & earnings, LENZ or VIRI?

Summary

How does Virios Therapeutics compare to Immunic?

Which has preferable earnings and valuation, IMUX or VIRI?

Does the media prefer IMUX or VIRI?

Do institutionals and insiders have more ownership in IMUX or VIRI?

Which has more risk and volatility, IMUX or VIRI?

Is IMUX or VIRI more profitable?

Do analysts prefer IMUX or VIRI?

Summary

How does Virios Therapeutics compare to Vivani Medical?

Do analysts prefer VIRI or VANI?

Does the media favor VIRI or VANI?

Which has more volatility and risk, VIRI or VANI?

Do insiders and institutionals hold more shares of VIRI or VANI?

Is VIRI or VANI more profitable?

Which has higher valuation and earnings, VIRI or VANI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIRI vs. The Competition

Virios Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools